ACE and systemic lupus erythematosus: Univariate LR identified 69 statistically significant metabolites distinct between patients with SLE‐P and patients with SLE‐NP (P<0.05) after controlling for ethnicity, age, age at diagnosis, disease duration, body mass index, BILAG, MAP, smoking status, diabetes, and current treatments (hydroxychloroquine, statins, angiotensin‐converting enzyme inhibitors, immunosuppressants, and prednisolone use and dosage [mg]; Figure S1).